Actively Recruiting
A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy
Led by Jinling Hospital, China · Updated on 2025-09-03
35
Participants Needed
1
Research Sites
141 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The objective of this single-center clinical study was to evaluate the disease control rate(DCR) and safety of multimodal radiotherapy in the treatment of patients with renal cell carcinoma (RCC) progressed after prior immunotherapy.
CONDITIONS
Official Title
A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Renal cell carcinoma confirmed by tissue examination, including unresectable or recurrent metastatic cases
- Disease progression or intolerance after 1-2 prior systemic therapies, including at least one regimen with immune checkpoint inhibitors and VEGFR-TKI drugs
- Progression within 12 months of prior immunoadjuvant or neoadjuvant therapy
- Eligible for radiotherapy as determined by physicians
- Able to tolerate sequential immunotherapy with radiation therapy
- At least two or more metastases at different sites measurable by RECIST v1.1
- Signed informed consent voluntarily
- ECOG performance status 0-1
- Good function of major organs
- Willing and able to follow study visits, treatments, lab tests, and sample collection
- Fertile women must use effective contraception during study and for at least 120 days after last dose, with negative pregnancy test within 7 days before enrollment
- Male patients not sterilized must use effective contraception during study and for at least 120 days after last dose
You will not qualify if you...
- History of other cancers within past 5 years except those expected to be cured (e.g., treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, breast ductal carcinoma in situ)
- Use of other antitumor treatments, including targeted or immunotherapy agents, within 4 weeks prior to study start
- Previous radiation therapy at any site
- Major surgery within 4 weeks prior to study start or still recovering
- History of severe drug allergies including antibody drugs
- Contraindications to restarting immunotherapy
- History of allogeneic organ or hematopoietic stem cell transplantation requiring long-term corticosteroids
- Uncontrolled severe diseases including severe autoimmune diseases, active CNS metastases, or significant liver disease
- Persistent toxicity from prior antitumor treatments not resolved to baseline or specified levels
- Use of systemic corticosteroids or immunosuppressive drugs within 14 days prior to treatment
- Renal failure needing dialysis
- History of immunodeficiency including HIV or organ transplantation
- Recent live attenuated vaccine within 4 weeks before study or planned during study
- History of psychotropic substance abuse or mental disorders
- Pregnant or breastfeeding women
- Any severe acute or chronic medical or psychiatric conditions that increase risk or interfere with study participation or results
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University
Nanjing, Jiangsu, China, 210000
Actively Recruiting
Research Team
L
Le Qu, M. D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here